# Ahura Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ahura

- Industry: Biotechnology
- Headquarters: Wilmington, US
- Website: www.ahurascientific.com
- Total disclosed funding: $32M
- Latest round: Series C (Mar 9, 2007)
- Investors on record: 4

## About

Ahura Corporation develops and provides portable analytical instruments for rapid chemical identification and material verification, serving various sectors including biopharma and industrial applications.Ahura Corporation was founded in 2002 and is headquartered in Wilmington, US. The company specializes in innovative analytical solutions. In January 2010, Thermo Fisher Scientific acquired Ahura Scientific for USD 145 mn. The founder, Lucia Diaz, has a history of entrepreneurial ventures in the technology sector.Ahura Corporation focuses on portable analytical instruments designed for quick and accurate chemical identification and material verification. Their core offerings utilize advanced technologies like X-ray fluorescence (XRF), near-infrared (NIR) spectroscopy, Raman spectroscopy, and Fourier-transform infrared (FTIR) spectroscopy. These analyzers provide actionable data within seconds, enabling users to make informed decisions in various environments, including biopharma, industrial applications, and laboratory diagnostics, targeting a diverse clientele across North America, Europe, and Asia.Ahura Corporation generates revenue through direct sales of its instruments, service agreements, and training programs. The company engages in B2B transactions, facilitating long-term partnerships that include equipment contracts and support services. Revenue streams also encompass subscriptions to software and analytics platforms that enhance product functionality, driven by structured deals that may offer volume discounts and tailored training services.Ahura Corporation aims to further develop its product line with upcoming new analytical instruments, although specific release dates are not disclosed. The company targets expansion into new markets, particularly in Europe and Asia, with plans to establish a stronger presence by 2023. The recent acquisition by Thermo Fisher Scientific will support these initiatives, leveraging resources to enhance product development and market reach.

## Funding rounds

- Series C, Mar 9, 2007, $7M — ARCH Venture Partners, Castile Ventures, Southern Ute Indian Tribe Growth Fund, Fuse Capital
- Series B, Jan 19, 2005, $10M — ARCH Venture Partners, Castile Ventures, Southern Ute Indian Tribe Growth Fund, Fuse Capital
- Series A, Oct 11, 2004, $15M — ARCH Venture Partners, Castile Ventures, Fuse Capital

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B, Series C
- Castile Ventures (https://capitalatlas.ai/funds/castile-ventures) — Series A, Series B, Series C
- Fuse Capital — Series A, Series B, Series C
- Southern Ute Indian Tribe Growth Fund — Series B, Series C